We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+11.56%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$1.09B
AUM Growth
+$152M
Cap. Flow
+$78.1M
Cap. Flow %
7.15%
Top 10 Hldgs %
44.59%
Holding
100
New
19
Increased
24
Reduced
16
Closed
28

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$27.9M
2
DGX icon
Quest Diagnostics
DGX
+$26.1M
3
CAH icon
Cardinal Health
CAH
+$20.8M
4
LLY icon
Eli Lilly
LLY
+$19.4M
5
CRL icon
Charles River Laboratories
CRL
+$15.3M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$19.6M
2
ASND icon
Ascendis Pharma A/S
ASND
+$15.6M
3
BPMC
Blueprint Medicines
BPMC
+$12.8M
4
KRYS icon
Krystal Biotech
KRYS
+$10.8M
5
BSX icon
Boston Scientific
BSX
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
76
BridgeBio Pharma
BBIO
$16.4B
– –
-100,000
Closed -$3.46M
BDX icon
77
Becton Dickinson
BDX
$49.4B
– –
-20,000
Closed -$4.58M
BMY icon
78
Bristol-Myers Squibb
BMY
$130B
– –
-100,000
Closed -$6.1M
BNTX icon
79
BioNTech
BNTX
$23.3B
– –
-40,000
Closed -$3.64M
BPMC
80
DELISTED
Blueprint Medicines
BPMC
– –
-145,000
Closed -$12.8M
CABA icon
81
Cabaletta Bio
CABA
$455M
– –
-850,000
Closed -$1.18M
CI icon
82
Cigna
CI
$72.4B
– –
-10,000
Closed -$3.29M
CRNX icon
83
Crinetics Pharmaceuticals
CRNX
$8.95B
– –
-125,000
Closed -$4.19M
DYN icon
84
Dyne Therapeutics
DYN
$4.99B
– –
-450,000
Closed -$4.71M
EWTX icon
85
CALL
Edgewise Therapeutics
EWTX
$4.81B
– –
-300,000
Closed -$6.6M
FATE icon
86
Fate Therapeutics
FATE
$319M
– –
-700,000
Closed -$553K
GILD icon
87
Gilead Sciences
GILD
$168B
– –
-175,000
Closed -$19.6M
GMED icon
88
Globus Medical
GMED
$11.4B
– –
-50,000
Closed -$3.66M
IQV icon
89
IQVIA
IQV
$40.1B
– –
-30,000
Closed -$5.29M
KRYS icon
90
Krystal Biotech
KRYS
$9.68B
– –
-60,000
Closed -$10.8M
LH icon
91
Labcorp
LH
$26.1B
– –
-20,000
Closed -$4.65M
MASI
92
DELISTED
Masimo
MASI
– –
-45,000
Closed -$7.5M
MREO
93
Mereo BioPharma
MREO
$48.8M
– –
-800,000
Closed -$1.8M
PTCT icon
94
PTC Therapeutics
PTCT
$6.15B
– –
-100,000
Closed -$5.1M
PTN
95
Palatin Technologies
PTN
$13.2M
– –
-20,000
Closed -$583K
RGEN icon
96
Repligen
RGEN
$9.3B
– –
-20,000
Closed -$2.54M
RNAM
97
PUT
DELISTED
Avidity Biosciences
RNAM
– –
-200,000
Closed -$5.9M
TEVA icon
98
Teva Pharmaceuticals
TEVA
$42.5B
– –
-500,000
Closed -$7.68M
VSTM icon
99
Verastem
VSTM
$638M
– –
-500,000
Closed -$3.02M
XENE icon
100
PUT
Xenon Pharmaceuticals
XENE
$6.11B
– –
-200,000
Closed -$6.71M
1 2 3
4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q2 2025 Portfolio in Review

As of Q2 2025, Integral Health Asset Management held 100 positions worth $1.09B, up 16% from $940M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Integral Health Asset Management deployed $78.1M of net new capital in Q2 2025, opening 19 new positions and adding to 24 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 50,000 shares worth $26.3M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier.

On the sell side, the largest reduction was Boston Scientific, an estimated $10.1M trimmed.

  • Integral Health Asset Management's largest Q2 2025 buy was Regeneron Pharmaceuticals: 50,000 shares worth $26.3M.
  • Integral Health Asset Management added most to BrightSpring Health Services in Q2 2025, an estimated $9.91M increase.
  • Integral Health Asset Management's biggest Q2 2025 reduction was Boston Scientific, cutting an estimated $10.1M.
  • Integral Health Asset Management fully exited Gilead Sciences in Q2 2025, selling an estimated $19.6M.
  • Integral Health Asset Management's ten largest holdings make up 45% of its $1.09B portfolio in Q2 2025.
  • Integral Health Asset Management opened 19 new positions and closed 28 in Q2 2025.
  • Integral Health Asset Management's portfolio value rose 16% quarter-over-quarter to $1.09B.

Based on Integral Health Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.